ArticleCureus2026
A Potential Case of Tetanus-Diphtheria Vaccine-Induced Immune Thrombocytopenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated platelet destruction. Vaccine-induced ITP, particularly the tetanus-diphtheria (Td) booster, is a well-documented phenomenon in children yet rare among adults. This report describes the case of a 48-year-old woman who presented with petechiae, palate and lingual bleeding, and gastrointestinal hemorrhage one week following Td booster vaccination, along with thrombocytopenia and leukocytosis. Except for uterine fibroids, she had an unremarkable medical history. Serological tests for dengue, HIV, hepatitis B, and hepatitis C, as well as a direct Coombs test, were performed to rule out alternative etiologies of ITP. An integral clinical approach and treatment with steroids and immunosuppressors, following three to four weeks, achieved clinical improvement of ITP. Previous cases and current analysis of the literature suggest molecular mechanisms and genetic factors as probable causes for this outcome; however, detailed clinical history together with environmental and clinical settings may allow for better characterization of this phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.